Prevalence of metabolic syndrome among Kaingang native americans in southern Brazil

The aim of this work was to evaluate the prevalence of metabolic syndrome, diabetes mellitus, and obesity among a Brazilian indigenous population. A cross-sectional study was carried out in 2008 among Kaingang native Americans from the central region of the state of Paraná, Brazil. Eighty two of the inhabitants aged 15 or older were selected. Height, weight, blood pressure, waistline circumference, and hip circumference were measured. After fasting, the blood was collected for the measurement of glucose, HDL cholesterol, triglyceride, total cholesterol, AI and B apolipoprotein, and hemoglobin. The prevalences found were: fasting hyperglycemia (9.8%), hypercholesterolemia (4.9%), reduced HDL cholesterol (13.4%), hypertriglyceridemia (11%), abdominal obesity (37.8%), generalized obesity (26.8%), arterial hypertension (26.8%), and anemia (46.3%). The prevalence of Metabolic Syndrome among the Kaingang was 11%, all in females 20 to 49 years of age. The results suggested that the changes in the indigenous lifestyle, especially in eating habits and physical activity, have occurred

Serum sclerostin levels in renal cell carcinoma patients with bone metastases

Sclerostin has been proposed as a potent inhibitor of bone formation. Sclerostin antibodies are under clinical development to treat osteoporosis and metastatic bone disease. Serum sclerostin level is elevated in multiple myeloma, an osteolytic malignancy, where it might serve as predictive marker for the use of sclerostin-directed antibodies. As renal cell carcinoma (RCC) patients often present with osteolytic metastases, we aimed to investigate serum sclerostin levels in RCC patients. Our study included 53 RCC patients (19 with bone metastases, 25 with visceral metastases and 9 with localized disease) and 53 age- and gender-matched non-osteoporotic controls. Frozen serum samples were subjected to sclerostin quantitative sandwich ELISA. The mean serum sclerostin levels of RCC patients and controls were 45.8 pmol/l and 45.1 pmol/l, respectively (p = 0.86). Analysis of variance showed no difference between the subgroups of RCC patients with regard to visceral or bone metastases or localized disease (p = 0.22). There was no significant association between eGFR (estimated glomerular filtration rate) and serum sclerostin levels in RCC patients (r = 0.05; p = 0.74) and controls (r = 0.06; p = 0.68). Our results indicate that serum sclerostin levels appear not to be a valuable biomarker to assess the occurrence of bone metastases in RCC patients